BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30624737)

  • 1. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms.
    Maiden MM; Hunt AMA; Zachos MP; Gibson JA; Hurwitz ME; Mulks MH; Waters CM
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29661867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.
    Moreau-Marquis S; Coutermarsh B; Stanton BA
    J Antimicrob Chemother; 2015 Jan; 70(1):160-6. PubMed ID: 25213272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 8. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
    Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K
    J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms.
    Nagant C; Tré-Hardy M; El-Ouaaliti M; Savage P; Devleeschouwer M; Dehaye JP
    Appl Microbiol Biotechnol; 2010 Sep; 88(1):251-63. PubMed ID: 20625718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O; Zorzi W; Jolois O; Elmoualij B; Duysens G; Cahay B; Streel B; Charif M; Bastin R; Heinen E; Quatresooz P
    Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizations of the viability and gene expression of dispersal cells from Pseudomonas aeruginosa biofilms released by alginate lyase and tobramycin.
    Daboor SM; Raudonis R; Cheng Z
    PLoS One; 2021; 16(10):e0258950. PubMed ID: 34695148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
    Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms.
    Borriello G; Richards L; Ehrlich GD; Stewart PS
    Antimicrob Agents Chemother; 2006 Jan; 50(1):382-4. PubMed ID: 16377718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
    Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS
    J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin.
    Eckert R; Brady KM; Greenberg EP; Qi F; Yarbrough DK; He J; McHardy I; Anderson MH; Shi W
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3833-8. PubMed ID: 16940063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
    Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.